Last reviewed · How we verify
NCT04514367
An Open Label Study of ANX005 in Subjects With, or at Risk for, Manifest Huntington's Disease
Completed
Phase 2
Last updated 31 January 2023
What this trial tests
Phase 2 trial testing ANX005 in Huntington Disease in 28 participants. Completed in 28 January 2022.
Timeline
17 August 2020
Primary endpoint
28 January 2022
28 January 2022
28 January 2022
Quick facts
| Lead sponsor | Annexon, Inc. |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 28 |
| Start date | 17 August 2020 |
| Primary completion | 28 January 2022 |
| Estimated completion | 28 January 2022 |
| Sites | 6 locations across United States |
Drugs / interventions tested
- ANX005 — full drug profile →
Conditions studied
- Huntington Disease — all drugs for Huntington Disease →
Sponsor
Annexon, Inc. — full company profile →
Who can join
18 and older, any sex, with Huntington Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is a multi-center, open-label study of intravenous (IV) ANX005 in subjects with, or at risk for, manifest Huntington's Disease (HD).
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Potential disease-modifying therapies for Huntington's disease: lessons learned and future opportunities.
Tabrizi SJ, Estevez-Fraga C, van Roon-Mom WMC, Flower MD, et al · · 2022 · cited 245× · PMID 35716694 · DOI 10.1016/s1474-4422(22)00121-1 -
New Avenues for the Treatment of Huntington's Disease.
Kim A, Lalonde K, Truesdell A, Gomes Welter P, et al · · 2021 · cited 130× · PMID 34445070 · DOI 10.3390/ijms22168363 -
Microglia and complement mediate early corticostriatal synapse loss and cognitive dysfunction in Huntington's disease.
Wilton DK, Mastro K, Heller MD, Gergits FW, et al · · 2023 · cited 114× · PMID 37814059 · DOI 10.1038/s41591-023-02566-3 -
Microglia mediate neurocognitive deficits by eliminating C1q-tagged synapses in sepsis-associated encephalopathy.
Chung HY, Wickel J, Hahn N, Mein N, et al · · 2023 · cited 100× · PMID 37235660 · DOI 10.1126/sciadv.abq7806 -
From Pathogenesis to Therapeutics: A Review of 150 Years of Huntington's Disease Research.
Jiang A, Handley RR, Lehnert K, Snell RG. · · 2023 · cited 88× · PMID 37629202 · DOI 10.3390/ijms241613021 -
Current and Possible Future Therapeutic Options for Huntington's Disease.
Ferguson MW, Kennedy CJ, Palpagama TH, Waldvogel HJ, et al · · 2022 · cited 66× · PMID 35615642 · DOI 10.1177/11795735221092517 -
Huntington's Disease: Complex Pathogenesis and Therapeutic Strategies.
Tong H, Yang T, Xu S, Li X, et al · · 2024 · cited 50× · PMID 38612657 · DOI 10.3390/ijms25073845 -
The complement system in neurodegenerative diseases.
Nimmo J, Byrne RAJ, Daskoulidou N, Watkins LM, et al · · 2024 · cited 41× · PMID 38505993 · DOI 10.1042/cs20230513
Verify or expand the search:
- PubMed search for NCT04514367
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of ANX005
Trials testing the same drug.
- NCT04691570 — Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ANX005 in Participants With Warm Autoimmune Hemolytic Ane · Phase 2 · completed
- NCT04569435 — Study of ANX005 in Adults With Amyotrophic Lateral Sclerosis (ALS) · Phase 2 · completed
- NCT04701164 — Efficacy and Safety of ANX005 in Subjects With Guillain-Barré Syndrome · Phase 3 · completed
- NCT04035135 — A Clinical Study of ANX005 and IVIG in Subjects With Guillain Barré Syndrome (GBS) · Phase 1 · completed
Other recruiting trials for Huntington Disease
Currently open trials in the same condition.
- NCT07326709 — A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease · Phase 3 · recruiting
- NCT07253038 — Evaluation of Three Tests to Assess Social Cognition in Huntington Disease · recruiting
- NCT06774443 — Hinting Task for Huntington's Disease · recruiting
- NCT06546488 — Cognitive Assessment Tools for Huntington's Disease. · recruiting
- NCT07010705 — Digital Measures for Clinical Trial Endpoints in Huntington's Disease · recruiting
Other Annexon, Inc. trials
Trials by the same sponsor.
- NCT07020819 — An Open Label Clinical Study to Evaluate Tanruprubart (Also Commonly Known as ANX005) in Participants With Guillain-Barr · Phase 3 · recruiting
- NCT06510816 — A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Parti · Phase 3 · active not recruiting
- NCT05780515 — A Study of ANX009 in Adult Participants With Lupus Nephritis · Phase 1 · completed
- NCT05521269 — Dose Study of ANX1502 in Healthy Volunteers · Phase 1 · completed
- NCT05288881 — Single Ascending Dose Study of ANX105 · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
Data sources for this page
- Trial protocol + status: ClinicalTrials.gov NCT04514367 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Annexon, Inc.
- Last refreshed: 31 January 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04514367.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing